2098|1|Public
25|$|<b>Neovascular</b> {{glaucoma}} {{results when}} new, abnormal vessels begin developing in {{the angle of}} the eye that begin blocking the drainage. Patients with such condition begin to rapidly lose their eyesight. Sometimes, the disease appears very rapidly, especially after cataract surgery procedures. A new treatment for this disease, as first reported by Kahook and colleagues, involves the use of a novel group of medications known as anti-VEGF agents. These injectable medications can lead to a dramatic decrease in new vessel formation and, if injected early enough in the disease process, may lead to normalization of intraocular pressure. Currently, there are no high-quality controlled trials demonstrating a beneficial effect of anti-VEGF treatments in lowering IOP in people with <b>neovascular</b> glaucoma.|$|E
25|$|Following {{the first}} report that carbon {{monoxide}} is a normal neurotransmitter in 1993, {{as well as one}} of three gases that naturally modulate inflammatory responses in the body (the other two being nitric oxide and hydrogen sulfide), carbon monoxide has received a great deal of clinical attention as a biological regulator. In many tissues, all three gases are known to act as anti-inflammatories, vasodilators, and encouragers of <b>neovascular</b> growth. However, the issues are complex, as <b>neovascular</b> growth is not always beneficial, since it plays a role in tumor growth, and also the damage from wet macular degeneration, a disease for which smoking (a major source of carbon monoxide in the blood, several times more than natural production) increases the risk from 4 to 6 times.|$|E
25|$|<b>Neovascular</b> glaucoma, an {{uncommon}} type of glaucoma, is difficult or {{nearly impossible to}} treat, and is often caused by proliferative diabetic retinopathy (PDR) or central retinal vein occlusion (CRVO). It may also be triggered by other conditions that result in ischemia of the retina or ciliary body. Individuals with poor {{blood flow to the}} eye are highly at risk for this condition.|$|E
25|$|As {{the disease}} progresses, severe nonproliferative {{diabetic}} retinopathy enters an advanced or proliferative (PDR) stage, where blood vessels proliferate/grow. The {{lack of oxygen}} in the retina causes fragile, new, blood vessels to grow along the retina and in the clear, gel-like vitreous humour that fills {{the inside of the}} eye. Without timely treatment, these new blood vessels can bleed, cloud vision, and destroy the retina. Fibrovascular proliferation can also cause tractional retinal detachment. The new blood vessels can also grow into the angle of the anterior chamber of the eye and cause <b>neovascular</b> glaucoma.|$|E
25|$|In biology, carbon {{monoxide}} is naturally {{produced by the}} action of heme oxygenase 1 and 2 on the heme from hemoglobin breakdown. This process produces a certain amount of carboxyhemoglobin in normal persons, even if they do not breathe any {{carbon monoxide}}. Following the first report that carbon monoxide is a normal neurotransmitter in 1993, as well as one of three gases that naturally modulate inflammatory responses in the body (the other two being nitric oxide and hydrogen sulfide), carbon monoxide has received a great deal of clinical attention as a biological regulator. In many tissues, all three gases are known to act as anti-inflammatories, vasodilators, and promoters of <b>neovascular</b> growth. Clinical trials of small amounts of carbon monoxide as a drug are ongoing. Too much carbon monoxide causes carbon monoxide poisoning.|$|E
2500|$|Other {{factors can}} cause glaucoma, known as [...] "secondary glaucoma", {{including}} prolonged use of steroids (steroid-induced glaucoma); conditions that severely restrict {{blood flow to}} the eye, such as severe diabetic retinopathy and central retinal vein occlusion (<b>neovascular</b> glaucoma); ocular trauma (angle-recession glaucoma); and inflammation of the middle layer of the pigmented vascular eye structure (uveitis), known as uveitic glaucoma.|$|E
5000|$|... #Subtitle level 2: <b>Neovascular</b> age-related macular {{degeneration}} ...|$|E
50|$|Bevacizumab has {{recently}} been used by ophthalmologists in an off-label use as an intravitreal agent {{in the treatment of}} proliferative (<b>neovascular)</b> eye diseases, particularly for choroidal <b>neovascular</b> membrane (CNV) in AMD. Although not currently approved by the FDA for such use, the injection of 1.25-2.5 mg of bevacizumab into the vitreous cavity has been performed without significant intraocular toxicity. Many retina specialists have noted impressive results in the setting of CNV, proliferative diabetic retinopathy, <b>neovascular</b> glaucoma, diabetic macular edema, retinopathy of prematurity and macular edema secondary to retinal vein occlusions.|$|E
5000|$|... #Subtitle level 4: AAV-based {{treatment}} for retinal <b>neovascular</b> diseases ...|$|E
50|$|In late AMD, enough retinal damage occurs {{that people}} have {{symptomatic}} central vision loss in addition to drusen. The damage can either be development of atrophy or the onset of <b>neovascular</b> disease. Late AMD is further divided into two subtypes based on the types of damage: Geographic atrophy and Wet AMD (also called <b>Neovascular</b> AMD).|$|E
5000|$|Pegaptanib (Macugen) - used {{to treat}} <b>neovascular</b> age-related macular {{degeneration}} (Pfizer, 2004) ...|$|E
5000|$|<b>Neovascular</b> {{glaucoma}} - glaucoma {{associated with}} vascular {{disease of the}} eye (often diabetes).|$|E
50|$|Rinucumab is a {{monoclonal}} antibody {{designed for the}} treatment of <b>neovascular</b> age-related macular degeneration.|$|E
50|$|Placental growth factor-expression within human {{atherosclerotic}} lesions {{is associated}} with plaque inflammation and <b>neovascular</b> growth.|$|E
50|$|At a later stage, pan-retinal {{photocoagulation}} (PRP) with an {{argon laser}} appears {{effective in reducing}} the <b>neovascular</b> components and their sequelae.|$|E
50|$|A Cochrane Review {{sought to}} {{determine}} whether interferon alfa-2a {{could be used as}} a treatment for individuals with <b>neovascular</b> age-related macular degeneration. They found no evidence of improved visual acuity with potential harm.|$|E
5000|$|Michels, S., Rosenfeld, P. J., Puliafito, C. A., Marcus, E. N., & Venkatraman, A. S. (2005). Systemic bevacizumab (Avastin) {{therapy for}} <b>neovascular</b> age-related macular degeneration: twelve-week {{results of an}} {{uncontrolled}} open-label clinical study. Ophthalmology, 112(6), 1035-1047.|$|E
5000|$|... 2006 - Lucentis (ranibizumab injection): Treatment of <b>neovascular</b> (wet) age-related macular {{degeneration}} (AMD). The FDA approved LUCENTIS after a Priority Review (six-month). Genentech started shipping product on June 30, 2006, {{the day the}} product was approved.|$|E
50|$|A {{selective}} EP4 antagonists {{significantly reduced}} corneal neovascularization in rats caused by oxygen-induced retinopathy or laser-induced choroidal neovascularization. This result suggests that EP4 activation contributes to corneal neovascularization and that EP4 antagonists {{may be useful}} for treating <b>neovascular</b> eye disease.|$|E
50|$|<b>Neovascular</b> {{glaucoma}} {{results when}} new, abnormal vessels begin developing in {{the angle of}} the eye that begin blocking the drainage. Patients with such condition begin to rapidly lose their eyesight. Sometimes, the disease appears very rapidly, especially after cataract surgery procedures. A new treatment for this disease, as first reported by Kahook and colleagues, involves the use of a novel group of medications known as anti-VEGF agents. These injectable medications can lead to a dramatic decrease in new vessel formation and, if injected early enough in the disease process, may lead to normalization of intraocular pressure. Currently, there are no high-quality controlled trials demonstrating a beneficial effect of anti-VEGF treatments in lowering IOP in people with <b>neovascular</b> glaucoma.|$|E
50|$|Choroidal neovascularization (CNV) is the {{creation}} of new blood vessels in the choroid layer of the eye. Choroidal neovascularization is a common cause of <b>neovascular</b> degenerative maculopathy (i.e. 'wet' macular degeneration) commonly exacerbated by extreme myopia, malignant myopic degeneration, or age-related developments.|$|E
50|$|Ranibizumab, a {{monoclonal}} antibody fragment (Fab) derived from bevacizumab, {{has been developed}} by Genetech for intraocular use. In 2006, FDA approved the drug {{for the treatment of}} <b>neovascular</b> age-related macular degeneration (wet AMD). The drug had undergone three successful clinical trials by then.|$|E
50|$|Treatment {{requires}} {{careful consideration}} of angiographic findings when a choroidal <b>neovascular</b> membrane is suspected {{which is a}} condition that responds to treatment. A vitreo-retinal specialist (an ophthalmologist specialized in treatment of retinal diseases) should be consulted for proper management of the case.|$|E
5000|$|Moshfeghi, A. A., Rosenfeld, P. J., Puliafito, C. A., Michels, S., Marcus, E. N., Lenchus, J. D., & Venkatraman, A. S. (2006). Systemic Bevacizumab (Avastin) Therapy for <b>Neovascular</b> Age-Related Macular Degeneration: Twenty-Four-Week Results of an Uncontrolled Open-Label Clinical Study. Ophthalmology, 113(11), 2002-2011.|$|E
50|$|In {{addition}} to treating wet-form age-related macular degeneration - aka. <b>neovascular</b> age-related macular degeneration, {{it has also}} been evaluated as a potential therapy for dry-form age related macular degeneration, as well as for reducing the intraocular pressure in eyes with ocular steroid injection-related glaucoma.|$|E
50|$|Bruch's {{membrane}} thickens with age, {{slowing the}} transport of metabolites. This {{may lead to the}} formation of drusen in age-related macular degeneration. There is also a buildup of deposits (Basal Linear Deposits or BLinD and Basal Lamellar Deposits BLamD) on and within the membrane, primarily consisting of phospholipids. The accumulation of lipids appears to be greater in the central fundus than in the periphery. This build up seems to fragment the membrane into a lamellar structure more like puff-pastry than a barrier. Inflammatory and <b>neovascular</b> mediators can then invite choroidal vessels to grow into and beyond the fragmented membrane. This <b>neovascular</b> membrane destroys the architecture of the outer retina and leads to sudden loss of central vision - wet age related macular degeneration.|$|E
50|$|Following {{the first}} report that carbon {{monoxide}} is a normal neurotransmitter in 1993, {{as well as one}} of three gases that naturally modulate inflammatory responses in the body (the other two being nitric oxide and hydrogen sulfide), carbon monoxide has received a great deal of clinical attention as a biological regulator. In many tissues, all three gases are known to act as anti-inflammatories, vasodilators, and encouragers of <b>neovascular</b> growth. However, the issues are complex, as <b>neovascular</b> growth is not always beneficial, since it plays a role in tumor growth, and also the damage from wet macular degeneration, a disease for which smoking (a major source of carbon monoxide in the blood, several times more than natural production) increases the risk from 4 to 6 times.|$|E
50|$|In many cases, {{people with}} MPGN II can develop drusen {{which is caused}} by same {{deposits}} within the Bruch's membrane beneath the retinal pigment epithelium (RPE) layer of the eye. Over time vision can deteriorate and subretinal <b>neovascular</b> membranes, macular detachment, and central serous retinopathy develop.|$|E
5000|$|In {{patients}} with the retinal disorder, <b>neovascular</b> age-related macular degeneration, local anti-VEGF treatment to limit the bio-activity of vascular endothelial growth factor {{has been shown to}} protect vision by limiting progression. In a wide range of cancers, treatment approaches have been studied, or are in development, aimed at decreasing tumour growth by reducing angiogenesis.|$|E
50|$|A 2016 Cochrane Review {{examined}} outcomes comparing aflibercept versus ranibizumab injections in over 2400 {{patients with}} <b>neovascular</b> AMD, from two randomized controlled trials. Both treatment options yielded similar improvements in visual acuity and morphological outcomes in patients, though the authors {{note that the}} aflibercept treatment regimen {{has the potential to}} reduce treatment burden other risks from injections.|$|E
50|$|If carotid {{occlusive}} disease {{results in}} ophthalmic artery occlusion, general ocular ischemia {{may result in}} retinal neovascularization, rubeosis iridis, cells and flare, iris necrosis, and cataract. The condition leads to neovascularization in various eye tissues due to the ischemia. The eye pressure may become high due to associated <b>neovascular</b> glaucoma. An ischemic optic neuropathy may eventually occur.|$|E
50|$|Off-label use of intravitreal bevacizumab {{has become}} a {{widespread}} treatment for <b>neovascular</b> age-related macular degeneration. Although the drug is not FDA-approved for non-oncologic uses, some studies suggest that bevacizumab is effective in increasing visual acuity with low rates of ocular adverse effects. However, due to small sample size and lack of randomized control trial, the result is not conclusive.|$|E
5000|$|Other {{factors can}} cause glaucoma, known as [...] "secondary glaucoma", {{including}} prolonged use of steroids (steroid-induced glaucoma); conditions that severely restrict {{blood flow to}} the eye, such as severe diabetic retinopathy and central retinal vein occlusion (<b>neovascular</b> glaucoma); ocular trauma (angle-recession glaucoma); and inflammation of the middle layer of the pigmented vascular eye structure (uveitis), known as uveitic glaucoma.|$|E
50|$|<b>Neovascular</b> glaucoma, an {{uncommon}} type of glaucoma, is difficult or {{nearly impossible to}} treat, and is often caused by proliferative diabetic retinopathy (PDR) or central retinal vein occlusion (CRVO). It may also be triggered by other conditions that result in ischemia of the retina or ciliary body. Individuals with poor {{blood flow to the}} eye are highly at risk for this condition.|$|E
5000|$|DR2 (15 or 16) -DQ6.2 {{has been}} found to {{associate}} with (idiopathic) narcolepsy-cataplexy [...] Hypocretin ligand deficiency in the brain and cerebrospinal fluid is also link to narcolepsy-cataplexy. DR15-DQ6 also shows an association with factors (including a genetic factor on chromosome 12p12) involved in familial multiple sclerosis DR15-DQ6 is strongly associated with the development of choroidal <b>neovascular</b> lesions in presumed ocular histoplasmosis syndrome.|$|E
50|$|DARPins {{have been}} used as {{research}} tools, as diagnostic agents and as therapeutic agents. Zurich-based Molecular Partners AG is currently pursuing the development of therapeutic DARPins. MP0112, the first DARPin candidate, is a vascular endothelial growth factor (VEGF) inhibitor and entered clinical trials for the treatment of wet age-related macular degeneration (wet AMD, also known as <b>neovascular</b> age-related macular degeneration) and diabetic macular edema in early 2010.|$|E
